Kaplan–Meier plots showing the power of stratification of ME1 expression for overall survival are shown in Figure 1C. AML patients with high ME1 expression had shorter survival compared to those with low expression (median OS of 21.5 vs. 53.9 months for TCGA, 18.9 months vs. not reached for BeatAML, and 18.4 vs. 145.9 months for HOVON). The gene discussed is ME1; the disease is acute myeloid leukemia.